Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TR64 in advanced solid tumors
NCT05649345Phase 1Recruiting
- Sponsor
- Tarapeutics Science Inc
- Start
- Jan 2023
- Primary completion
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of TR64 in solid tumor, sponsored by Tarapeutics Science Inc. Primary endpoints: Adverse Events and Serious Adverse Events, Dose Limited Toxicities at 28 days and 2 more. Started Jan 2023; status: recruiting.
02
Drugs
TR64
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05649345.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05649345.